Recent studies have found that gefitinib, an inhibitor of EGF receptor (EGFR), can significantly improve peritoneal fibrosis in experimental mouse models by inhibiting STAT3 phosphorylation.21 The gene discussed is EGFR; the disease is Peritoneal Fibrosis.